159 related articles for article (PubMed ID: 21575258)
1. Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer.
Davis SJ; Choong DY; Ramakrishna M; Ryland GL; Campbell IG; Gorringe KL
BMC Cancer; 2011 May; 11():173. PubMed ID: 21575258
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
3. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.
Milde-Langosch K; Ocon E; Becker G; Löning T
Int J Cancer; 1998 Feb; 79(1):61-5. PubMed ID: 9495360
[TBL] [Abstract][Full Text] [Related]
4. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression.
Ahn YH; Yang Y; Gibbons DL; Creighton CJ; Yang F; Wistuba II; Lin W; Thilaganathan N; Alvarez CA; Roybal J; Goldsmith EJ; Tournier C; Kurie JM
Mol Cell Biol; 2011 Nov; 31(21):4270-85. PubMed ID: 21896780
[TBL] [Abstract][Full Text] [Related]
5. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.
Gorringe KL; Choong DY; Williams LH; Ramakrishna M; Sridhar A; Qiu W; Bearfoot JL; Campbell IG
Neoplasia; 2008 Nov; 10(11):1253-8. PubMed ID: 18953434
[TBL] [Abstract][Full Text] [Related]
6. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
Liu XD; Zhang ZW; Wu HW; Liang ZY
Pathol Res Pract; 2021 Jan; 217():153313. PubMed ID: 33341545
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.
Spillman MA; Lacy J; Murphy SK; Whitaker RS; Grace L; Teaberry V; Marks JR; Berchuck A
Gynecol Oncol; 2007 May; 105(2):312-20. PubMed ID: 17276500
[TBL] [Abstract][Full Text] [Related]
8. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
Schmid G; Notaro S; Reimer D; Abdel-Azim S; Duggan-Peer M; Holly J; Fiegl H; Rössler J; Wiedemair A; Concin N; Altevogt P; Marth C; Zeimet AG
BMC Cancer; 2016 Feb; 16():102. PubMed ID: 26879132
[TBL] [Abstract][Full Text] [Related]
9. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer.
Wrzeszczynski KO; Varadan V; Byrnes J; Lum E; Kamalakaran S; Levine DA; Dimitrova N; Zhang MQ; Lucito R
PLoS One; 2011; 6(12):e28503. PubMed ID: 22174824
[TBL] [Abstract][Full Text] [Related]
10. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
11. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
12. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.
Kuo KT; Guan B; Feng Y; Mao TL; Chen X; Jinawath N; Wang Y; Kurman RJ; Shih IeM; Wang TL
Cancer Res; 2009 May; 69(9):4036-42. PubMed ID: 19383911
[TBL] [Abstract][Full Text] [Related]
13. Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.
Barton CA; Gloss BS; Qu W; Statham AL; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
Br J Cancer; 2010 Jan; 102(1):87-96. PubMed ID: 19935792
[TBL] [Abstract][Full Text] [Related]
14. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications.
Gorringe KL; Jacobs S; Thompson ER; Sridhar A; Qiu W; Choong DY; Campbell IG
Clin Cancer Res; 2007 Aug; 13(16):4731-9. PubMed ID: 17699850
[TBL] [Abstract][Full Text] [Related]
15. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.
Imura M; Yamashita S; Cai LY; Furuta J; Wakabayashi M; Yasugi T; Ushijima T
Cancer Lett; 2006 Sep; 241(2):213-20. PubMed ID: 16303245
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
17. Homozygous deletion of MKK4 in ovarian serous carcinoma.
Nakayama K; Nakayama N; Davidson B; Katabuchi H; Kurman RJ; Velculescu VE; Shih IeM; Wang TL
Cancer Biol Ther; 2006 Jun; 5(6):630-4. PubMed ID: 16627982
[TBL] [Abstract][Full Text] [Related]
18. High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas.
Benetkiewicz M; Wang Y; Schaner M; Wang P; Mantripragada KK; Buckley PG; Kristensen G; Børresen-Dale AL; Dumanski JP
Genes Chromosomes Cancer; 2005 Mar; 42(3):228-37. PubMed ID: 15578687
[TBL] [Abstract][Full Text] [Related]
19. Overexpressed microRNA-136 works as a cancer suppressor in gallbladder cancer through suppression of JNK signaling pathway via inhibition of MAP2K4.
Niu J; Li Z; Li F
Am J Physiol Gastrointest Liver Physiol; 2019 Nov; 317(5):G670-G681. PubMed ID: 31369289
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
